<DOC>
	<DOCNO>NCT00688844</DOCNO>
	<brief_summary>HYPOTHESIS : The investigator hypothesize KuvanTM therapy could influence nutritional body composition parameter neurotransmitter concentration pediatric adult PKU subject . SUMMARY : Though investigator know KuvanTM lower blood Phe level improve tolerance natural protein least half PKU ( Phenylketonuria ) patient population , investigator know full effect medicine patient 's diet , impact medicine diet change body composition nutrient status PKU patient . Since KuvanTM may also help body produce neurotransmitter , investigator also want find take KuvanTM change neurotransmitter level PKU patient , PKU patient benefit KuvanTM feel le stigmatized good outlook life result treatment . Therefore , research study several objective . These investigate impact KuvanTM therapy ( 1 ) body composition parameter PKU patient : lean body mass , percent body fat , bone density , weight gain , growth ( 2 ) dietary change , effect change , intake calorie essential nutrient ( 3 ) change blood biomarkers certain nutrient ( 4 ) blood urine neurotransmitter level , since change could indicate improved neurological functioning , ( 5 ) quality life PKU patient , may feel less burden due dietary freedom KuvanTM provide .</brief_summary>
	<brief_title>Nutritional Neurotransmitter Changes PKU Subjects BH4</brief_title>
	<detailed_description>BACKGROUND : Tetrahydrobiopterin ( BH4 ) treatment option newly available phenylketonuria ( PKU ) patient within United States pharmaceutical KuvanTM . This small molecule function cofactor multiple enzyme system , include metabolism phenylalanine tyrosine enzyme phenylalanine hydroxylase ( PAH ) . HYPOTHESIS : The investigator hypothesize KuvanTM therapy could influence nutritional body composition parameter neurotransmitter concentration pediatric adult PKU subject . OBJECTIVES : 1 . To record nutritional biomarkers , body composition , bone density , measure nutrient intake phenylketonuria subject group baseline one year start KuvanTM therapy . 2 . To investigate change monoamine neurotransmitter synthesis phenylketonuria subject group baseline one year start KuvanTM therapy . 3 . Evaluate change quality life ( QOL ) PKU subject begin KuvanTM therapy METHODOLOGY : Investigators intend enroll 60 PKU patient , age 4 adulthood , plan begin BH4 treatment prescribe medical provider . Patients give 4 week demonstrate response KuvanTM determine drop plasma PHE ≥15 % . All patient , regardless response KuvanTM , allow continue study . All subject follow full 12 month monitor nutrient intake , nutritional biomarkers , serotonin catecholamine level , QOL . Two-tailed statistical analysis α=0.05 use compare result responder nonresponders , well compare follow-up value baseline measure .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Neurotransmitter Agents</mesh_term>
	<criteria>Diagnosed PKU ability provide inform consent ( legal guardian provide inform consent ) least 4 year age planning try BH4 treatment Pregnant unable provide inform consent le 4 year age currently take BH4</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>PKU</keyword>
	<keyword>Phenylketonuria</keyword>
	<keyword>BH4</keyword>
	<keyword>Kuvan</keyword>
	<keyword>Tetrahydrobiopterin</keyword>
	<keyword>Sapropterin Dihydrochloride</keyword>
	<keyword>Nutrition</keyword>
	<keyword>PHE</keyword>
	<keyword>Phenylalanine</keyword>
	<keyword>PAH</keyword>
	<keyword>Phenylalanine hydroxylase</keyword>
	<keyword>Neurotransmitters</keyword>
	<keyword>Serotonin</keyword>
	<keyword>Catecholamines</keyword>
	<keyword>Diet</keyword>
	<keyword>Body Fat</keyword>
	<keyword>Bone Density</keyword>
</DOC>